Scisparc and clearmind collaboration strengthens ip portfolio with patent application in the u.s. for treatment of depression

The application refers to a novel psychedelic-based combination of clearmind's meai and scisparc's cannamide™
SPRC Ratings Summary
SPRC Quant Ranking